BRPI0912246A2 - Composto, composição farmacêutica, e, usos de uma composição farmacêutica e de um composto. - Google Patents

Composto, composição farmacêutica, e, usos de uma composição farmacêutica e de um composto.

Info

Publication number
BRPI0912246A2
BRPI0912246A2 BRPI0912246-0A BRPI0912246A BRPI0912246A2 BR PI0912246 A2 BRPI0912246 A2 BR PI0912246A2 BR PI0912246 A BRPI0912246 A BR PI0912246A BR PI0912246 A2 BRPI0912246 A2 BR PI0912246A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BRPI0912246-0A
Other languages
English (en)
Inventor
Pier Giovanni Baraldi
Allan R Moorman
Romeo Romagnoli
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of BRPI0912246A2 publication Critical patent/BRPI0912246A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0912246-0A 2008-05-08 2009-05-08 Composto, composição farmacêutica, e, usos de uma composição farmacêutica e de um composto. BRPI0912246A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5139908P 2008-05-08 2008-05-08
US5379308P 2008-05-16 2008-05-16
US12/437,344 US20090281145A1 (en) 2008-05-08 2009-05-07 Allosteric enhancers of the a1 adenosine receptor
PCT/US2009/043320 WO2009137782A2 (en) 2008-05-08 2009-05-08 Allosteric enhancers of the a1 adenosine receptor

Publications (1)

Publication Number Publication Date
BRPI0912246A2 true BRPI0912246A2 (pt) 2015-07-28

Family

ID=41265447

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912246-0A BRPI0912246A2 (pt) 2008-05-08 2009-05-08 Composto, composição farmacêutica, e, usos de uma composição farmacêutica e de um composto.

Country Status (11)

Country Link
US (2) US20090281145A1 (pt)
EP (1) EP2326175A4 (pt)
JP (1) JP2011519955A (pt)
KR (1) KR20110042030A (pt)
CN (1) CN102088849A (pt)
AU (1) AU2009244115A1 (pt)
BR (1) BRPI0912246A2 (pt)
CA (1) CA2723146A1 (pt)
IL (1) IL209007A0 (pt)
MX (1) MX2010011843A (pt)
WO (1) WO2009137782A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739588B (zh) * 2014-01-04 2015-07-01 新发药业有限公司 一种2-氨基噻吩衍生物的简便合成方法
KR20210042689A (ko) 2019-10-10 2021-04-20 삼성전자주식회사 화합물 및 이를 포함하는 광전 소자, 이미지 센서 및 전자 장치
WO2022256097A1 (en) * 2021-06-04 2022-12-08 Cytometix, Inc. Method of dosing a pain therapeutic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332732A (en) * 1992-09-11 1994-07-26 Mcneilab, Inc. Thiophene and pyridine antipsychotic agents
EP0595150B1 (de) * 1992-10-29 1996-07-31 Hoechst Aktiengesellschaft Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen
US6323214B1 (en) * 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
US6727258B2 (en) * 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
US6489356B2 (en) * 2000-09-05 2002-12-03 Edward Leung Method for treating pain in humans
US6248774B1 (en) * 2000-09-05 2001-06-19 King Pharmaceuticals Research & Development, Inc. Method for treating hyper-excited sensory nerve functions in humans
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
US7196106B2 (en) * 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
CA2723146A1 (en) 2009-11-12
US20120108636A1 (en) 2012-05-03
WO2009137782A3 (en) 2009-12-30
EP2326175A4 (en) 2011-09-28
WO2009137782A2 (en) 2009-11-12
CN102088849A (zh) 2011-06-08
KR20110042030A (ko) 2011-04-22
JP2011519955A (ja) 2011-07-14
AU2009244115A1 (en) 2009-11-12
IL209007A0 (en) 2011-01-31
US20090281145A1 (en) 2009-11-12
EP2326175A2 (en) 2011-06-01
MX2010011843A (es) 2010-11-30

Similar Documents

Publication Publication Date Title
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI1010768A2 (pt) composto, e, composição farmacêutica.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0916069A2 (pt) "composto, usos de um composto, composição farmacêutica, composição cosmética e usos cosméticos de uma composição"
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
BRPI0919165A2 (pt) composição farmacêutica,e, uso de um composto
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.